Zac-Varghese, Sagen
Mark, Patrick
Bain, Steve
Banerjee, Debasish
Chowdhury, Tahseen A.
Dasgupta, Indranil
De, Parijat
Fogarty, Damian
Frankel, Andrew
Goldet, Gabrielle
Karalliedde, Janaka
Mallik, Ritwika
Montero, Rosa
Sharif, Adnan
Wahba, Mona
Dhatariya, Ketan
McCafferty, Kieran
Lioudaki, Eirini
Winocour, Peter
Article History
Received: 26 April 2024
Accepted: 1 July 2024
First Online: 6 July 2024
Declarations
:
: Not applicable.
: Not applicable.
: • PM reports receiving speaker fees and attending advisory board from Vifor, AstraZeneca, Pharmacomsos, Napp, Novartis, and Astellas and receiving grants from Boehringer Ingelheim. • SB reports receiving personal fees from Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, and Sanofi Aventis and being a shareholder in Glycosmedia. • DB reports receiving speaker fees from Vifor Pharma; honoraria for advisory board from Bayer; and research grant from AstraZeneca. • ID reports receiving research grants from Medtronic and Sanofi-Genzyme, receiving honoraria for attending advisory board and speaker meetings from GlaxoSmithKline, AstraZeneca, and Sanofi-Genzyme, and being the national lead for 3 GSK trials. • PD reports receiving honoraria for advisory work and/or lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Napp Pharmaceuticals, Novo Nordisk, and Sanofi. • DF reports receiving honoraria for delivering educational meetings and/or attending advisory boards for AstraZeneca, Napp, Boehringer Ingelheim, and Vifor Pharmaceuticals. • JK reports receiving research grants from AstraZeneca and Sanofi and receiving speaker fees and attending advisory boards from Boehringer Ingelheim, AstraZeneca, Sanofi, and Napp. • KM reports receiving speaker fees and attending advisory board from Vifor, AstraZeneca, Bayer, Boehringer Ingelheim, Pharmacomsos, Napp, Vifor Fresenius and receiving a grant from AstraZeneca. • PW reports receiving honoraria for delivering educational meetings and/or attending advisory boards for Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Napp, Sanofi, Novo, and Vifor Pharmaceuticals. • All the other authors declared no competing interests.